Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluating the Effectiveness, Safety, and Feasibility of Stationary Ultra-Slow Running in Treating MASLD Patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| In-Place Slow Jogging Group | Experimental | During the 3-month intervention period, the diet followed the outpatient health prescription of MASLD, and ultra-jogging training was carried out 5 times a week, and each training session lasted for 30 minutes. |
|
| Control Group | No Intervention | During the 3-month intervention period, the diet followed the health prescription of our MASLD outpatient clinic, and patients were encouraged to maintain their daily physical activity level, such as walking up and down stairs, walking short distances, etc. However, there is no in-situ ultra-jogging intervention. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| In-Place Slow Jogging | Behavioral | ultra-jogging training was carried out 5 times a week, and each training session lasted for 30 minutes. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Liver Stiffness Measurement (LSM) | Measure method：FibroScan | Baseline, 3 months post-treatment |
| Controlled Attenuation Parameter(CAP) | Measure method：FibroScan | Baseline, 3 months post-treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Polysomnography metrics | Measure method:Polysomnography（PSG) | Baseline, 3 months post-treatment |
| Height | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lan L Zhong | Contact | +8613162099450 | lanzhong@tongji.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shanghai East Hospital | Shanghai | Shanghai Municipality | 200120 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Body Weight | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Waist Circumference | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Body Fat Percentage | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Lean Body Mass | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| BMI | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| albumin | The unit is grams per liter (g/L). It reflects liver synthetic function and nutritional status. Normal reference values are 35-50 g/L for adults and 34-48 g/L for individuals aged 60 years or older.Time | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Hemoglobin | The unit is grams per liter (g/L). It is used to assess anemia or polycythemia. Normal reference values are as follows: adult males: 120-160 g/L; adult females: 110-150 | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| body temperature | The unit is degrees Celsius (℃). Normal range: axillary temperature is 36℃ to 37℃.Time Frame: Baseline, at 1 week, 4 weeks, 8 weeks, and 12 weeks after | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Respiratory Rate | The unit is breaths per minute (breaths/min). Normal range: adults, 16-20 breaths/min (at rest).Tachypnea may be caused by reasons such as pneumonia, fever, cardiovascular diseases, anemia, etc., while bradypnea may be caused by reasons such as increased intracranial pressure, hypothyroidism, etc. | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Blood Pressure | The unit is millimeters of mercury (mmHg). Normal range: systolic pressure, 90-139 mmHg; diastolic pressure, 60-89 mmHg. | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Heart Rate | The unit is beats per minute (beats/min). Normal range: 60-100 beats/min (at rest). | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Blood White Blood Cells | Normal range for adults is 4.0-10.0×10⁹/L. An elevated level may indicate bacterial infection or inflammation, while a decreased level may be associated with viral infections or drug reactions. | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Bloos Red Blood Cells | Normal range is 4.3-5.8×10¹²/L for males and 3.8-5.1×10¹²/L for females. | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Platelets | Normal range is 125-350×10⁹/L. A reduced count increases the risk of bleeding, while an elevated count increases the risk of thrombosis. | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| alanine aminotransferase (ALT) | Normal range is 7-40 U/L. Elevated levels indicate liver damage.Time | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| aspartate aminotransferase (AST) | Normal range is 13-35 U/L. Elevated levels indicate liver damage. | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| serum creatinine (Cr) | Normal range is 53-106 μmol/L for males and 44-97 μmol/L for females. Elevated levels suggest decreased renal function. | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Blood Urea Nitrogen (BUN) | Normal range is 2.9-7.5 mmol/L. Elevated levels may be associated with renal failure or dehydration. | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Total Cholesterol (TC) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Triglycerides (TG) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| High-Density Lipoprotein Cholesterol（HDL) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Fasting Blood Glucose (FBG) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Fasting Insulin (FINS) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Hyaluronic Acid（HA) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Procollagen III N-Terminal Peptide（PIIINP) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Collagen Type IV（CIV) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Laminin（LN) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |
| Glycated Hemoglobin (HbA1c) | Baseline, 1 months post-treatment, 2 months post-treatment, 3 months post-treatment |